login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
| Disease Info Index | ||||||||||||||||||||||||||
|
|
Breast Cancer
Page Options
Drugs For Breast Cancer
anastrozole
cyclophosphamide
docetaxel
everolimus
exemestane
letrozole
methotrexate
vinorelbine tartrate
Breast Cancer / Carcinoma of the Breast
Latest Publication and Research on Breast Cancer
|
|
|
Text 
|
Attenuation of Cytotoxic Natural Product DNA Intercalating Agents by Caffeine. Hill GM, Moriarity DM, Setzer WN Department of Chemistry, University of Alabama in Huntsville, Huntsville, Alabama 35899, USA. Many anti-tumor drugs function by intercalating into DNA. The xanthine alkaloid caffeine can also intercalate into DNA as well as form p-p molecular c... Read More Source: PubMed Attenuation of Cytotoxic Natural Product DNA Intercalating Agents by Caffeine. Hill GM, Moriarity DM, Setzer WN Department of Chemistry, University of Alabama in Huntsville, Huntsville, Alabama 35899, USA. Many anti-tumor drugs function by intercalating into DNA. The xanthine alkaloid caffeine can also intercalate into DNA as well as form p-p molecular c... Read More Source: PubMed RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J, Miller CR, Vigil D, Graves LM, Der CJ Department of Pharmacology; University of North Carolina at Chapel Hill; Chapel Hill, NC. Previous studies described functional roles for Rho GDP dissociation inhibitor 2 (RhoGDI2) in bladder, gastric and breast cancers. However, only limit... Read More Source: PubMed RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J, Miller CR, Vigil D, Graves LM, Der CJ Department of Pharmacology; University of North Carolina at Chapel Hill; Chapel Hill, NC. Previous studies described functional roles for Rho GDP dissociation inhibitor 2 (RhoGDI2) in bladder, gastric and breast cancers. However, only limit... Read More Source: PubMed PLoS ONE Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. Jung HJ, Park JY, Jeon HS, Kwon TH Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Taegu, South Korea. Aquaporin (AQP) is a family of transmembrane proteins for water transport. Recent studies revealed that AQPs are likely to play a role in tumor progre... Read More Source: PubMed PLoS ONE Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. Jung HJ, Park JY, Jeon HS, Kwon TH Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Taegu, South Korea. Aquaporin (AQP) is a family of transmembrane proteins for water transport. Recent studies revealed that AQPs are likely to play a role in tumor progre... Read More Source: PubMed 2011 Dec 5 Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R Institut Curie-Hôpital René Huguenin, Service d'Oncogénétique, U735 INSERM-Saint-Cloud, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon-Centre Léon Bérard, Lyon, INSERM U1052, CNRS UMR5286, Université Lyon 1, Centrede Recherche en Cancérologie de Lyon, Lyon, INSERM U827-Montpellier, CHU Montpellier, Hôpital Arnaud de Villeneuve, Laboratoire de Génétique Moléculaire-Montpellier and Université Montpellier1, UFR Médecine-Montpellier, F-34000, France. BRCA1 and BRCA2 are the two main genes responsible for predisposition to breast and ovarian cancers, as a result of protein-inactivating monoallelic m... Read More Source: PubMed 2011 Dec 5 Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R Institut Curie-Hôpital René Huguenin, Service d'Oncogénétique, U735 INSERM-Saint-Cloud, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon-Centre Léon Bérard, Lyon, INSERM U1052, CNRS UMR5286, Université Lyon 1, Centrede Recherche en Cancérologie de Lyon, Lyon, INSERM U827-Montpellier, CHU Montpellier, Hôpital Arnaud de Villeneuve, Laboratoire de Génétique Moléculaire-Montpellier and Université Montpellier1, UFR Médecine-Montpellier, F-34000, France. BRCA1 and BRCA2 are the two main genes responsible for predisposition to breast and ovarian cancers, as a result of protein-inactivating monoallelic m... Read More Source: PubMed 2011 Dec 5 MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S, Sahin O Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. MicroRNA-200c (miR-200c) has been shown to suppress epithelial-to-mesenchymal transition (EMT), which is mainly attributed to targeting of ZEB1/ZEB2, ... Read More Source: PubMed 2011 Dec 5 The impact of obesity on follow-up after an abnormal screening mammogram. Schur EA, Elmore JG, Tracy O, Wernli KJ, Sickles E, Haneuse S 1Medicine, University of Washington. BACKGROUND: Effective breast cancer screening and early detection are crucial for obese women, who experience a higher incidence of the disease and p... Read More Source: PubMed 2011 Dec 5 Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles DM, Nevanlinna H, Ramus SJ, Spurdle M, Robson ME, Sherman ME, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Golgar DE, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Cilius Nielsen F, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Canadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox SB, Rebbeck TR, Rubinstein WS, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr RA, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko AP, Imyanitov EN, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse TA, Caligo MA, Aretini P, Rantala J, von Wachenfeld A, Henriksson K, Steele L, Neuhausen SL, Nussbaum B, Beattie MS, Odunsi KO, Sucheston LE, Gayther SA, Nathanson KL, Gross J, Walsh CS, Karlan BY, Chenevix-Trench G, Easton DF, Antoniou AC 1Public Health and Primary Care, Cambridge University. BackgroundPrevious small studies found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers ... Read More Source: PubMed 2011 Dec 5 Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Eliassen AH, Spiegelman D, Xu X, Keefer LK, Veenstra TD, Barbieri RL, Willett WC, Hankinson SE, Ziegler RG Channing Laboratory, Harvard School of Medicine and Brigham and Women's Hospital. Endogenous estrogens and estrogen metabolism are hypothesized to be associated with premenopausal breast cancer risk but evidence is limited. We exami... Read More Source: PubMed Cancer Prev Res (Phila) Molecular biomarkers of risk in premalignancy and breast cancer prevention. Allred DC Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8118, St. Louis, MO 63110. dcallred@path.wustl.edu. About 50,000 U.S. women are diagnosed with breast atypical hyperplasia each year, giving them about a six-fold increased relative risk of developing i... Read More Source: PubMed 2011 Dec 5 Psammoma bodies in fine needle aspiration cytology of the breast: A clinicopathological study of 30 cases. Pillai KR, Mani KS, Jayalal KS, Preethi TR, Somanathan T, Jayasree K Division of Pathology, Regional Cancer Centre, Thiruvananathapuram, Kerala 695011, India. ravikrcc@yahoo.co.in. Psammoma bodies (PBs) in breast lesions are rare and little is known about the role of these structures in breast pathology. This study has looked in ... Read More Source: PubMed 2011 Dec 5 MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S, Sahin O Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. MicroRNA-200c (miR-200c) has been shown to suppress epithelial-to-mesenchymal transition (EMT), which is mainly attributed to targeting of ZEB1/ZEB2, ... Read More Source: PubMed 2011 Dec 5 The impact of obesity on follow-up after an abnormal screening mammogram. Schur EA, Elmore JG, Tracy O, Wernli KJ, Sickles E, Haneuse S 1Medicine, University of Washington. BACKGROUND: Effective breast cancer screening and early detection are crucial for obese women, who experience a higher incidence of the disease and p... Read More Source: PubMed 2011 Dec 5 Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles DM, Nevanlinna H, Ramus SJ, Spurdle M, Robson ME, Sherman ME, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Golgar DE, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Cilius Nielsen F, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Canadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox SB, Rebbeck TR, Rubinstein WS, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr RA, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko AP, Imyanitov EN, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse TA, Caligo MA, Aretini P, Rantala J, von Wachenfeld A, Henriksson K, Steele L, Neuhausen SL, Nussbaum B, Beattie MS, Odunsi KO, Sucheston LE, Gayther SA, Nathanson KL, Gross J, Walsh CS, Karlan BY, Chenevix-Trench G, Easton DF, Antoniou AC 1Public Health and Primary Care, Cambridge University. BackgroundPrevious small studies found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers ... Read More Source: PubMed 2011 Dec 5 Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Eliassen AH, Spiegelman D, Xu X, Keefer LK, Veenstra TD, Barbieri RL, Willett WC, Hankinson SE, Ziegler RG Channing Laboratory, Harvard School of Medicine and Brigham and Women's Hospital. Endogenous estrogens and estrogen metabolism are hypothesized to be associated with premenopausal breast cancer risk but evidence is limited. We exami... Read More Source: PubMed Cancer Prev Res (Phila) Molecular biomarkers of risk in premalignancy and breast cancer prevention. Allred DC Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8118, St. Louis, MO 63110. dcallred@path.wustl.edu. About 50,000 U.S. women are diagnosed with breast atypical hyperplasia each year, giving them about a six-fold increased relative risk of developing i... Read More Source: PubMed 2011 Dec 5 Psammoma bodies in fine needle aspiration cytology of the breast: A clinicopathological study of 30 cases. Pillai KR, Mani KS, Jayalal KS, Preethi TR, Somanathan T, Jayasree K Division of Pathology, Regional Cancer Centre, Thiruvananathapuram, Kerala 695011, India. ravikrcc@yahoo.co.in. Psammoma bodies (PBs) in breast lesions are rare and little is known about the role of these structures in breast pathology. This study has looked in ... Read More Source: PubMed |
| Share it! |  |
 |
 |
 |
 |
 |
 |
|
|
Comment & Contribute
|
Posted by:
BenedictPaulC
Posted on: 05/03/2012 Saying incidence of breast cancer [or any disease] is high in western world is meaningless. In India, we do not have proper statistics in any hospital. We do not have well established Biostatistics dept in any of our hospitals/universities. Moreover, we do not have any proper centralized system of collecting such data as they have in the US as NIH. Apart from this, still more than 65% of our population are in rural areas where basic treatment itself is at stake. So, we do not have any rights whatsoever to comment on the western world.
Reply |
Forward
Posted by:
dr.anita
Posted on: 09/20/2009 I agree.I have been conducting training programmes for women on early detction of breast cancer.Main focus has been breast sed to about 9000 women over the past 3 years.If there is nothing much we can do for prevention then early detection has to be the main focus. dr.anita khokhar.M.D. |
Medwonders Health Network
| Citing this Health Article | ||||||
|
||||||
| News on Breast Cancer |
|
Botanical Formula Slows Breast Cancer Metastasis |
|
Cardio-Pulmonary Function can be a Strong Indicator for Survival Chances of Breast Cancer Patients |
|
Post Surgery Will the Tumour Return? New Breast Cancer Test to Predict Exactly |
|
Heat Shock Protein Inhibitor And Hormonal Therapy Combo Tested in Breast Cancer Clinical Trial |
|
HDAC Inhibitor Successfully Targets and Destroys Triple Negative Breast Cancer |
| Total News Item 1543 | |
Are you a member of Facebook? Become a fan of Medindia and get breaking news delivered to your Facebook page.
